Supriya Lifescience posts 50% revenue jump, clears USFDA inspection
Quarterly revenue hit ₹277 crore, net profit rose 47% to ₹74 crore. The Lote facility received a VAI classification from the USFDA.
What's new
- Q4 revenue jumped 50% YoY to ₹277 crore; net profit rose 47% to ₹74 crore.
- USFDA issued a Voluntary Action Indicated classification for the Lote facility after a surprise inspection.
- Contrast media product launch delayed to H2 FY27; cardiovascular order book of 300 MT ramps over 2-3 years.
Why this matters
The results show Supriya is scaling fast, and the USFDA clearance removes a key overhang for its largest facility. The cardiovascular order book provides multi-year revenue visibility. The guidance of ₹1,000 crore in revenue for FY27 now hinges on the contrast media delay being absorbed by the rest of the portfolio.
What we're watching
- Whether the contrast media delay compresses the ₹1,000 crore revenue target for FY27.
- Ramp-up timeline for the 300 MT cardiovascular intermediate order.
- Market reaction to the VAI classification, which is not a clean 'no action' finding.
The full read
Supriya Lifescience's Q4 numbers are strong. Revenue grew 50% to ₹277 crore, and net profit climbed 47% to ₹74 crore. The bigger news is regulatory: the USFDA issued a Voluntary Action Indicated classification for its Lote facility after a surprise inspection, a result that allows continued operations but requires corrective actions. Management is sticking to guidance of ~20% annual revenue growth and a 33-35% EBITDA margin for FY27, targeting ₹1,000 crore in revenue. But the launch of a key contrast media product is delayed to the second half of the year, putting pressure on the rest of the portfolio to deliver. The cardiovascular intermediate order book of 300 MT will ramp over 2-3 years, adding a steadier growth stream. The transcript adds operational color, but no new strategic shifts beyond the product delay.
Questions answered
- What was the outcome of the USFDA inspection at the Lote facility?
- The facility received a Voluntary Action Indicated (VAI) classification. This means the USFDA found deviations that require correction but is not imposing a mandatory shutdown. Management said one minor observation was already resolved.
- Why was the contrast media product launch pushed back?
- The company did not provide a specific reason on the call. The launch was moved from Q1/Q2 to the second half of FY27, which could affect the phasing of its FY27 revenue target.
- How does the cardiovascular order book affect the growth story?
- The order book is for 300 metric tons of a cardiovascular intermediate. Management said it will ramp over two to three years, providing multi-year volume growth in that segment.
- What does the 33-35% EBITDA margin guidance imply?
- At ₹1,000 crore of revenue, it implies an EBITDA of ₹330-350 crore for FY27. This would require the company to maintain current profitability while integrating new product launches.